HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Rosalin Mishra und 4 weiteren Autor:innen. Beteiligte Einrichtung: James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Receptor, ErbB-3, Mutation, Cell Proliferation, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Cancer society.
Abstract (Originalsprache)
HER3 is mutated in ~2%–10% of cancers depending on the cancer type. We found the HER3‐V104L mutation to be activating from patient‐derived mutations introduced via lentiviral transduction in HER3KO HER2 + HCC1569 breast cancer cells in which endogenous HER3 was eliminated by CRISPR/Cas9. Cells expressing HER3‐V104L showed higher p‐HER3 and p‐ERK1/2 expression versus cells expressing wild‐type HER3 or HER3‐V104M. Patients whose tumor expressed the HER3 V104L variant had a reduced probability of overall survival compared to patients lacking a HER3 mutation whereas we did not find a statistically significant difference in overall survival of various cancer patients with the HER3 V104M mutation. Our data showed that HER2 inhibitors suppressed cell growth of HCC1569HER3KO cells stably expressing the HER3‐V104L mutation. Cancer cell lines (SNU407, UC15 and DV90) with endogenous HER3‐V104M mutation showed reduced cell proliferation and p‐HER2/p‐ERK1/2 expression with HER2 inhibitor treatment. Knock down of HER3 abrogated cell proliferation in the above cell lines which were overall more sensitive to the ERK inhibitor SCH779284 versus PI3K inhibitors. HER3‐V104L mutation stabilized HER3 protein expression in COS7 and SNUC5 cells. COS7 cells transiently transfected with the HER3‐V104L mutation in the presence of HER binding partners showed higher expression of p‐HER3, p‐ERK1/2 versus HER3‐WT in a NRG‐independent manner without any change in AKT signaling. Overall, this study shows the clinical relevance of the HER3 V104L and the V104M mutations and its response to HER2, PI3K and ERK inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
Förderung
- American Cancer society
Zitieren
APA
Mishra, R., Kilroy, M. K., Feroz, W., Patel, H., & Garrett, J. T. (2024). HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23743
Vancouver
Mishra R, Kilroy MK, Feroz W, Patel H, Garrett JT. HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23743
BibTeX
@article{Mishra2024,
author = {Mishra, Rosalin and Kilroy, Mary Kate and Feroz, Wasim and Patel, Hima and Garrett, Joan T},
title = {HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23743}
}
EUVIMED